Imatinib provides a second example of serendipitious target discovery. ... The broad kinome profiling of clinically approved and investigational kinase inhibitors is likely to help identify such ...

Conclusions: The 10-year follow-up analysis of the binimetinib plus imatinib combination phase II study demonstrated robust and sustained clinical benefit in PFS, OS and DSS for patients with ...

Together, ziftomenib plus imatinib may enhance KIT recycling while reducing KIT transcription. This combination is currently being investigated clinically in patients with imatinib-sensitive and ...

BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered clinical-stage biopharma company, today announced that the company will present groundbreaking research across ...

A new FTC report claims that pharmacy benefit managers generated $7.3bn by marking up specialty generics used to treat diseases like cancer and HIV.

Gene-testing specialist Editas Medicine has halted development of its lead clinical programme for congenital eye disorders after it generated lacklustre results in a phase 1/2 trial. The ...

FDA scientists have recently reviewed severe liver injury with TKIs; the US prescribing information for imatinib, erlotinib, lapatinib, nilotinib, sunitinib and pazopanib contains warnings related ...

Use WebMD's drug interaction checker to find which medications, vitamins, or supplements may be unsafe to combine.

At present, PROTACs have garnered significant attention as a burgeoning therapeutic approach. Relying on endogenous E3 ubiquitin ligases, PROTACs achieve the catalytic degradation of target proteins ...

Imatinib, a drug used for the treatment of chronic myeloid leukemia and other cancers, works by blocking the catalytic site of pathological constitutively active Abl kinase. While the binding pose is ...